Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial

• Published in: Journal of the American College of Cardiology Vol. 62; no. 13; pp. 1154 - 1162
• Main Authors: BALLANTYNE, Christie M, DAVIDSON, Michael H, MACDOUGALL, Diane E, BAYS, Harold E, DICARLO, Lorenzo A, ROSENBERG, Noah L, MARGULIES, Janice, NEWTON, Roger S
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier 24.09.2013
• Subjects: Aged; AMP-Activated Protein Kinases - drug effects; ATP Citrate (pro-S)-Lyase - antagonists & inhibitors; Biological and medical sciences; Cardiology. Vascular system; Dicarboxylic Acids - administration & dosage; Dicarboxylic Acids - adverse effects; Disorders of blood lipids. Hyperlipoproteinemia; Double-Blind Method; Fatty Acids - administration & dosage; Fatty Acids - adverse effects; Female; Heart; Humans; Hypercholesterolemia - drug therapy; Hypolipidemic Agents - administration & dosage; Hypolipidemic Agents - adverse effects; Male; Medical sciences; Metabolic diseases; Middle Aged; Risk Factors; Toxicity; Multicenter study; Non-specific serine/threonine protein kinase; Citrate; Lipids; Cardiovascular disease; Hyperlipoproteinemia; Lyases; Lipoprotein; Result; Randomization; Efficiency; Complication; Clinical trial; Safety; Dyslipemia; Cardiology; Human; Modulator; Enzyme; Transferases; Metabolic diseases; Patient; Cholesterol; Hypercholesterolemia; Adenosine kinase; Placebo; Double blind study; Circulatory system; ATP; apo; cardiovascular disease; apolipoprotein; risk factors; LDL-C; low-density lipoprotein cholesterol; ACL; high-sensitivity C-reactive protein; mITT; adenosine triphosphate-citrate lyase; HDL-C; upper limit of normal; ULN; high-density lipoprotein cholesterol; hsCRP; AMPK; adenosine monophosphate-activated protein kinase; modified intent-to-treat; prevention

The aim of this study was to assess the lipid-altering efficacy and safety of ETC-1002 in subjects with hypercholesterolemia. ETC-1002 is a small molecule that modulates pathways of cholesterol, fatty acid, and carbohydrate metabolism and may have therapeutic benefits in treating hypercholesterolemi...